Tags

Type your tag names separated by a space and hit enter

Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
Mov Disord. 2004 Oct; 19(10):1256-8.MD

Abstract

Amantadine suppressed severe levodopa-induced choreic dyskinesia, which developed at initiation of levodopa therapy, in two siblings manifesting dystonia with motor delay phenotype of GTP cyclohydrolase I deficiency caused by compound heterozygous GCH1 mutations. Our finding suggests a beneficial effect of amantadine on this type of dyskinesia frequently observed in relatively severe dopamine-deficient metabolic disorders.

Authors+Show Affiliations

Movement Disorders Research Laboratory, Centre for Addiction and Mental Health-Clarke Division, Toronto, Ontario, Canada. yoshiaki_furukawa@camh.netNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15389992

Citation

Furukawa, Yoshiaki, et al. "Amantadine for Levodopa-induced Choreic Dyskinesia in Compound Heterozygotes for GCH1 Mutations." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 19, no. 10, 2004, pp. 1256-8.
Furukawa Y, Filiano JJ, Kish SJ. Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations. Mov Disord. 2004;19(10):1256-8.
Furukawa, Y., Filiano, J. J., & Kish, S. J. (2004). Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations. Movement Disorders : Official Journal of the Movement Disorder Society, 19(10), 1256-8.
Furukawa Y, Filiano JJ, Kish SJ. Amantadine for Levodopa-induced Choreic Dyskinesia in Compound Heterozygotes for GCH1 Mutations. Mov Disord. 2004;19(10):1256-8. PubMed PMID: 15389992.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations. AU - Furukawa,Yoshiaki, AU - Filiano,James J, AU - Kish,Stephen J, PY - 2004/9/25/pubmed PY - 2005/2/16/medline PY - 2004/9/25/entrez SP - 1256 EP - 8 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 19 IS - 10 N2 - Amantadine suppressed severe levodopa-induced choreic dyskinesia, which developed at initiation of levodopa therapy, in two siblings manifesting dystonia with motor delay phenotype of GTP cyclohydrolase I deficiency caused by compound heterozygous GCH1 mutations. Our finding suggests a beneficial effect of amantadine on this type of dyskinesia frequently observed in relatively severe dopamine-deficient metabolic disorders. SN - 0885-3185 UR - https://www.unboundmedicine.com/medline/citation/15389992/Amantadine_for_levodopa_induced_choreic_dyskinesia_in_compound_heterozygotes_for_GCH1_mutations_ L2 - https://doi.org/10.1002/mds.20194 DB - PRIME DP - Unbound Medicine ER -